CoronaVac, are safe and produce a strong antibody response among children and adolescents aged 3-17 years, according to a study published in The Lancet Infectious Diseases journal. Methods Interpretation CoronaVac was well tolerated and safe and induced humoral responses in children and adolescents aged 3–17 years.
Neutralising antibody titres induced by the 3·0 μg dose were higher than those of the 1·5 μg dose. The results support the use of 3·0 μg dose with a two-immunisation schedule for further studies in children and adolescents. Adverse events Among the 550 participants who received at least one dose of vaccine or the control, adverse reactions within 28 days occurred in 56 (26 per cent) of 219 participants in the 1.5μg group.